肝素治疗脓毒症诱导的弥散性血管内凝血(HepSIC)的有效性与安全性:多中心随机对照试验研究方案
本研究为多中心、双盲、安慰剂对照随机试验,计划纳入600例符合脓毒症3.0标准且疑似弥散性血管内凝血(DIC)的患者,按1:1随机接受普通肝素(UFH)或生理盐水持续静脉给药7天,主要结局为ICU死亡率,旨在评估UFH在脓毒症相关DIC中的有效性与安全性。
要点
- DIC发生于30-50%的脓毒症患者,是ICU高死亡率的重要原因。
- 试验计划纳入600例脓毒症3.0标准且疑似DIC患者,1:1随机接受UFH或生理盐水持续静脉给药7天。
- 主要结局为ICU死亡率,次要结局包括28天全因死亡率、SOFA评分改善及大出血发生率。
核心结论
- HepSIC试验旨在评估普通肝素(UFH)在中国不同地区脓毒症相关DIC患者中的有效性与安全性。
- 小剂量UFH给药可能为治疗脓毒症相关凝血障碍提供新的潜在方法。
研究设计与样本
- 多中心、双盲、安慰剂对照随机试验,计划招募600例符合脓毒症3.0标准且疑似DIC的患者。
- 参与者按1:1随机接受UFH或生理盐水,入组后6小时内开始持续静脉给药,疗程7天。
- 研究者、参与者和统计学家对分组设盲。
- 伦理批准由20个参与中心的伦理委员会授予。
- 试验注册于ClinicalTrials.gov(NCT02654561),注册日期为2016年1月13日。
主要发现
- DIC发生于30-50%的脓毒症患者,并导致ICU高死亡率。
- 实验和临床数据显示脓毒症可能从普通肝素(UFH)治疗中获益。
- 迄今尚无大型多中心试验确定UFH在疑似DIC脓毒症患者中的安全性和有效性。
关键数值与推荐
- 主要结局为ICU死亡率。
- 次要结局包括28天全因死亡率、序贯器官衰竭评估(SOFA)评分的改善以及大出血的发生率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Disseminated intravascular coagulation (DIC) occurs in 30-50% of septic patients and contributes to high mortality in the intensive care unit (ICU). However, there are few proven interventions for coagulation disorder management in sepsis. Experimental and clinical data have demonstrated that sepsis could benefit from unfractionated heparin (UFH) treatment. To date, there are no large multicenter trials to determine the safety and efficacy of UFH in septic patients with suspected DIC. METHODS: A multicenter, double-blinded, placebo-controlled randomized trial is designed to recruit 600 patients who met sepsis 3.0 criteria and suspected DIC. Participants will be randomized (1:1) to receive UFH or saline via continuous intravenous administration for 7 days within 6 h of enrolment. The primary outcome is ICU mortality. The secondary outcome includes 28-day all-cause mortality, the improvement of Sequential Organ Failure Assessment scores, and the incidence of major hemorrhage. Investigators, participants, and statisticians will be blinded to the allocation. DISCUSSION: The HepSIC trial is to evaluate the efficacy and safety of UFH on sepsis-related DIC across different areas of China. The small dosage of UFH administration would offer a new potential approach for treating sepsis-related coagulation disorders. ETHICS AND DISSEMINATION: Ethical approval was granted by all the ethics committees of 20 participant centers. Results will be disseminated via peer-reviewed publications and presented at conferences. TRIAL REGISTRATION: ClinicalTrials.gov NCT02654561. Registered on 13 January 2016.
引用
- Sun Y, Ding R, Sun H, et al. Efficacy and safety of heparin for sepsis-induced disseminated intravascular coagulation (HepSIC): study protocol for a multicenter randomized controlled trial. Trials. 2024. PMID: 38167115. doi:10.1186/s13063-023-07853-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。